However, it is noteworthy that the patient was on an optimized background regimen including raltegravir. Recent evidence shows that combinations of new drugs including etravirine are efficacious

in multidrug-resistant adolescents [12]. Twenty-one (91%) patients received at least two fully active SGI-1776 mw drugs including etravirine with one or more new boosted drugs (maraviroc and/or raltegravir in 10 of 23 patients; 43%). The favourable response observed in patients who received combination therapy with new drugs may be attributable to the combination and not only to etravirine. Thus, in resource-constrained settings with limited drug options, these results might not be applicable. However, 11 (47%) of our patients, although receiving two fully active drugs, only received etravirine as a new drug (combined mainly with atazanavir, emtricitabine or tenofovir), suggesting that the favourable outcome was attributable to etravirine. These results may be applicable in settings with limited drug options. The only adverse effect of etravirine was mild/moderate skin rash, which was self-limiting

and did not lead to treatment discontinuation. It should be noted that the biochemical abnormalities were associated with protease inhibitors. Although the small sample size is the main shortcoming of the present work and further analyses involving larger cohorts are necessary, our study is the most long-term study ever performed in adolescents and the first to evaluate Alpelisib datasheet the efficacy of etravirine-based therapy in children. Further paediatric studies involving patients harbouring non-B subtype viruses are of paramount importance to examine selleck etravirine use in resource-limited settings. In conclusion, we observed a sustained antiviral response and improved immunological parameters in a group of multidrug-resistant paediatric patients, most of whom received etravirine as a component of salvage regimens with at least two fully

active drugs. However, special consideration should be given to the management of patients with non-B subtypes in order to obtain an additional etravirine resistance mutation panel. Hospitals in which the patients were treated were: Hospital General Universitario ‘Gregorio Marañón’, Madrid (seven patients), Hospital Universitario ‘Doce de Octubre’, Madrid (five patients), Hospital ‘Virgen del Rocio’, Seville (five patients), Hospital Regional Universitario ‘Carlos Haya’, Malaga (three patients), Hospital Universitario de Getafe, Madrid (two patients) and Hospital Universitario ‘La Paz’, Madrid (one patient). Hospital General Universitario ‘Gregorio Marañón’: V. Briz, C. Palladino, S. J. de Ory, D. García Alonso, M. D. Gurbindo, M. L. Navarro, J. Saavedra and M. A. Muñoz-Fernández. Hospital Universitario ‘Doce de Octubre’: I.